Baek‐Yeol Ryoo

17.3k citations
349 papers · 10.1k indexed · 6 hit papers · h-index 50
Topics
Hepatocellular Carcinoma Treatment and Prognosis (108 papers)Gastric Cancer Management and Outcomes (78 papers)Pancreatic and Hepatic Oncology Research (70 papers)

In The Last Decade

Baek‐Yeol Ryoo

342 papers receiving 10.0k citations

Hit Papers

Pembrolizumab As Second-Line Therapy in Patients With A...2015202620182022201920152022201820224008001.2k

Peers

Baek‐Yeol Ryoo
Comparison fields: 5 of 116
  • Oncology 4.8k
  • Hepatology 3.9k
  • Pulmonary and Respiratory Medicine 3.3k
  • Pathology and Forensic Medicine 2.3k
  • Surgery 2.1k
Replace Ho Yeong Lim with:
Ho Yeong Lim South Korea
Joon Oh Park South Korea
Marinela Capanu United States
Christophe Louvet France
David Malka France
Tomoo Kosuge Japan
Sara Lonardi Italy
Joan Maurel Spain
Ari David Baron United States
Jean‐Luc Van Laethem Belgium
Baek‐Yeol Ryoo relative to Ho Yeong Lim South Korea Ho Yeong Lim's profile →
Citations per field
00.5×1.5×
Ho Yeong Lim · 1×
Citations per year

Countries citing papers authored by Baek‐Yeol Ryoo

Since Specialization
Citations

This map shows the geographic impact of Baek‐Yeol Ryoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baek‐Yeol Ryoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baek‐Yeol Ryoo more than expected).

Fields of papers citing papers by Baek‐Yeol Ryoo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baek‐Yeol Ryoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baek‐Yeol Ryoo. The network helps show where Baek‐Yeol Ryoo may publish in the future.

Co-authorship network of co-authors of Baek‐Yeol Ryoo

This figure shows the co-authorship network connecting the top 25 collaborators of Baek‐Yeol Ryoo. A scholar is included among the top collaborators of Baek‐Yeol Ryoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baek‐Yeol Ryoo. Baek‐Yeol Ryoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 1
3 29
4 4
5 1
6
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trialbreakdown →
127
7 68
8 28
9 22
10 78
11 34
12 31
13 35
14 25
15
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trialbreakdown →
1300
16 34
17 4
18 73
19 55
20 96

About Baek‐Yeol Ryoo

Baek‐Yeol Ryoo is a scholar working on Hepatology, Gastroenterology and Oncology, having authored 349 papers that have together received 10.1k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Gastric Cancer Management and Outcomes (78 papers) and Pancreatic and Hepatic Oncology Research (70 papers). The work is most often cited by research in Hepatology (3.9k citations), Gastroenterology (989 citations) and Oncology (4.8k citations). Baek‐Yeol Ryoo has collaborated with scholars based in South Korea, United States and Taiwan. Frequent co-authors include Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo, Andrew X. Zhu, Masatoshi Kudo, Ann‐Lii Cheng, Ho Yeong Lim, Richard S. Finn, Thomas Yau and Han Chu Lee. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026